Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
XRP Price Risks Fall To $0.75 As Top Chartist Warns Of Bearish Setup

XRP Price Risks Fall To $0.75 As Top Chartist Warns Of Bearish Setup

CryptoNewsNetCryptoNewsNet2026/05/28 13:57
By:CryptoNewsNet
Back to the list

XRP Price Risks Fall To $0.75 As Top Chartist Warns Of Bearish Setup

XRP Price Risks Fall To $0.75 As Top Chartist Warns Of Bearish Setup image 0  newsbtc.com 12 m
XRP Price Risks Fall To $0.75 As Top Chartist Warns Of Bearish Setup image 1

$XRP’s weekly chart is flashing a bearish continuation risk after failing to reclaim the $1.60 area, according to veteran chartist Aksel Kibar, CMT. His latest XRPUSD setup points to a possible extension lower toward $0.75 if the current consolidation breaks down.

Kibar, who posts under the TechCharts account on X, is a Chartered Market Technician and classical chart trader with more than 15 years of experience in global equity market analysis. He’s an ex-fund manager who has worked for Yapi Kredi Bank in Turkey and the National Bank of Abu Dhabi, where he worked as a senior technical analyst and fund manager.

His reputation in technical-analysis circles has also been reinforced by Peter Brandt, the veteran commodity trader and author, who has repeatedly amplified Kibar’s work as “the most accomplished pure classical chart analyst alive today.”

$XRP Stalls Below $1.60 Resistance

His latest $XRP post was short but direct. “$XRPUSD 1.6 resistance. Latest consolidation below the resistance and can act as a bearish continuation.”

XRP Price Risks Fall To $0.75 As Top Chartist Warns Of Bearish Setup image 2 $XRP price analysis | Source: X @TechCharts

The chart shows $XRP on Bitstamp’s weekly timeframe, trading around $1.28 after failing to reclaim the $1.60 region. That level matters because it marks a prior support zone from the broader 2025 range, which extended toward the $3.45 area at the top. Once $XRP lost that range support, the same zone began acting as overhead resistance.

The more important detail is the structure forming beneath it. $XRP is not merely trading below $1.60; it has been compressing inside what resembles a triangular consolidation. The upper boundary slopes lower from the failed recovery attempt, while the lower boundary rises from the post-breakdown lows.

In classical charting, that kind of structure can resolve either way, but its location matters. A triangle forming after a major breakdown and below former support is often treated as a potential continuation pattern unless buyers force a recovery back above resistance.

Kibar’s $0.75 target appears to come from the pattern’s measured move. The widest part of the triangle spans roughly from $1.67 down to $1.12, giving the structure a height of about $0.55. If $XRP breaks below the triangle near the $1.30 area, subtracting that $0.55 range gives a downside objective near $0.75.

That makes the target less arbitrary than a simple horizontal support call. It is the projected extension of the current compression if the market confirms a breakdown. The setup still requires that confirmation. Without a decisive break below the triangle, the chart remains a risk structure rather than a completed bearish signal.

The chart also includes Kibar’s long-term trend filter. In crypto, Kibar is known to use the 365-day exponential moving average as a primary directional filter rather than as a standalone buy or sell trigger. Price above that average generally supports a more constructive bias; price below it argues for caution, particularly when rallies stall below resistance.

In $XRP’s case, price is trading below the red long-term moving average at $1.74, while the average itself sits above the current consolidation. That adds another layer to the bearish interpretation. Buyers not only need to invalidate the triangle breakdown risk; they also need to repair the broader trend structure by reclaiming lost resistance and moving back above the long-term average.

At press time, $XRP traded at $1.29.


$XRP remains above key support, 1-day chart | Source: XRPUSDT on TradingView.com
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.

华尔街见闻•2026/11/06 13:42
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight

Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.

华尔街见闻•2026/11/06 13:23

Eli Lilly (LLY.US) "lowers its stance" and joins forces with former rival Hims (HIMS.US) to compete for the self-pay weight loss drug market

Eli Lilly is collaborating with Hims & Hers Health, leveraging the telehealth company’s large customer base to expand access to its blockbuster weight loss drugs and boost sales of medications, including its new oral weight loss drug Foundayo.

智通财经•2026/11/06 12:37
Eli Lilly (LLY.US) "lowers its stance" and joins forces with former rival Hims (HIMS.US) to compete for the self-pay weight loss drug market